Relmada Therapeutics said Thursday that its experimental treatment for depression failed to achieve the primary goals of a large clinical trial, a significant setback for the company’s only medicine in clinical development.
The drug, a pill called REL-1017, did not show a statistically significant, anti-depressive benefit compared with a placebo.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
